ROS-mediated platelet generation: A microenvironment-dependent manner for megakaryocyte proliferation, differentiation, and maturation

Cell Death and Disease

Volumn 4, Issue 7, 2013, Pages

  Chen, S ^a   Su, Y ^a   Wang, J ^a  

^a State Key Laboratory of Trauma   (China)

Author keywords

Megakaryocytopoiesis; Microenvironment; Platelet activation; Reactive oxygen species; Regulation

Indexed keywords

REACTIVE OXYGEN METABOLITE;

APOPTOSIS; BONE MARROW; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; INFLAMMATION; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84881043526     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.253     Document Type: Review

References (137)

1. Bluteau D, Lordier L, Di Stefano A, Chang Y. Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost 2009; 7: 227-234.
2. Thon JN, Italiano JE. Platelet formation. Semin Hematol 2010; 47: 220-226.
3. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol 2013; 35: 254-261.
4. Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets 2010; 21: 360-367.
5. Feng W, Madajka M, Kerr BA, Mahabeleshwar GH, Whiteheart SW, Byzova TV. A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing. Blood 2011; 117: 3893-3902.
6. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-134.
7. Reems JA, Pineault N, Sun S. In vitro megakaryocyte production and platelet biogenesis: state of the art. Transfus Med Rev 2010; 24: 33-43.
8. Botton SD, Sabri S, Daugas E, Zermati Y, Guidotti JE, Kroemer G et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002; 100: 1310-1317.
9. Sasaki H, Hirabayashi Y, Ishibashi T, Inoue T, Matsuda M, Kai S et al. Effects of erythropoietin, IL-3, IL-6 and LIF on a murine megakaryoblastic cell line: growth enhancement and expression of receptor mRNAs. Leuk Res 1995; 19: 95-102.
10. Burstein SA, Mei RL, Henthorn J, Friese P, Turner K. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 1992; 153: 305-312.
11. Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire J, Schaub R et al. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 1993; 81: 901-908.
12. Pang L, Weiss MJ, Poncz M. Megakaryocyte biology and related disorders. J Clin Invest 2005; 115: 3332-3338.
13. Majka M, Janowska-Wieczorek A, Ratajczak J, Kowalska MA, Vilaire G, Pan ZK et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood 2000; 96: 4142-4151.
14. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
15. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
16. Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003; 50: 1129-1146.
17. Giorgio M, Trinei M, Migliaccio E, Pelicci PG. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol 2007; 8: 722-728.
18. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 31: 170-180.
19. Lacy F, Gough DA, Schmid-Schonbein GW. Role of xanthine oxidase in hydrogen peroxide production. Free Radic Biol Med 1998; 25: 720-727.
20. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999; 43: 521-531.
21. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978; 4: 7-25.
22. Scadden DT. The stem-cell niche as an entity of action. Nature 2006; 441: 1075-1079.
23. Bianco P. Bone and the hematopoietic niche: a tale of two stem cells. Blood 2011; 117: 5281-5288.
24. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010; 7: 150-161.
25. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006; 124: 407-421.
26. Nagasawa T, Omatsu Y, Sugiyama T. Control of hematopoietic stem cells by the bone marrow stromal niche: the role of reticular cells. Trends Immunol 2011; 32: 315-320.
27. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nature 2008; 8: 290-301.
28. Fuchs E, Tumbar T, Guasch G. Socializing with the neighbors: stem cells and their niche. Cell 2004; 116: 769-778.
29. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005; 21: 605-631.
30. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-161.
31. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004; 103: 3258-3264.
32. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology 2005; 20: 349-356.
33. Li W, Johnson SA, Shelley WC, Yoder MC. Hematopoietic stem cell repopulating ability can be maintained in vitro by some primary endothelial cells. Exp Hematol 2004; 32: 1226-1237.
34. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64-71.
35. Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 2001; 81: 685-696.
36. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007; 104: 5431-5436.
37. Hermitte F, Brunet de la Grange P, Belloc F, Praloran V, Ivanovic Z. Very low O2 concentration (0.1%) favors G0 return of dividing CD34\+ cells. Stem Cells 2006; 24: 65-73.
38. Ivanovic Z, Dello Sbarba P, Trimoreau F, Faucher JL, Praloran V. Primitive human HPCs are better maintained and expanded in vitro at 1 percent oxygen than at 20 percent. Transfusion 2000; 40: 1482-1488.
39. Tauro S, Hepburn MD, Bowen DT, Pippard MJ. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001; 86: 1038-1045.
40. Wang W, Gou L, Xie G, Tong A, He F, Lu Z et al. Proteomic analysis of interstitial fluid in bone marrow identified that peroxiredoxin 2 regulates H(2)O(2) level of bone marrow during aging. J Proteome Res 2010; 9: 3812-3819.
41. Unwin RD, Smith DL, Blinco D, Wilson CL, Miller CJ, Evans CA et al. Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood 2006; 107: 4687-4694.
42. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 2010; 7: 391-402.
43. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
44. Danet GH, Pan Y, Luongo JL, Bonnet DA, Simon MC. Expansion of human SCID-repopulating cells under hypoxic conditions. J Clin Invest 2003; 112: 126-135.
45. Roy S, Tripathy M, Mathur N, Jain A, Mukhopadhyay A. Hypoxia improves expansion potential of human cord blood-derived hematopoietic stem cells and marrow repopulation efficiency. Eur J Haematol 2012; 88: 396-405.
46. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25-27.
47. Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM et al. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 2010; 7: 606-617.
48. Nakata S, Matsumura I, Tanaka H, Ezoe S, Satoh Y, Ishikawa J et al. NF-kB family proteins participate in multiple steps of hematopoiesis through elimination of reactive oxygen species. J Biol Chem 2004; 279: 55578-55586.
49. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007; 128: 325-339.
50. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R et al. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. EMBO J 2010; 29: 4118-4131.
51. Rizo A, Olthof S, Han L, Vellenga E, de Haan G, Schuringa JJ. Repression of BMI1 in normal and leukemic human CD34\+ cells impairs self-renewal and induces apoptosis. Blood 2009; 114: 1498-1505.
52. Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007; 1: 101-112.
53. Jing Z, Ping Z, Yi L, Yin X, Jie W, Lingbo L. The cross-talk between ROS and p38MAPKa in the ex vivo expanded human umbilical cord blood CD133\+ cells. J Huazhong Univ Sci Technol 2011; 31: 591-595.
54. Urao N, Inomata H, Razvi M, Kim HW, Wary K, McKinney R et al. Role of nox2-based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia. Circ Res 2008; 103: 212-220.
55. Tesio M, Golan K, Corso S, Giordano S, Schajnovitz A, Vagima Y et al. Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood 2011; 117: 419-428.
56. Grek CL, Townsend DM, Tew KD. The impact of redox and thiol status on the bone marrow: pharmacological intervention strategies. Pharmacol Ther 2011; 129: 172-184.
57. Piccoli C, Ria R, Scrima R, Cela O, D'Aprile A, Boffoli D et al. Characterization of mitochondrial and extra-mitochondrial oxygen consuming reactions in human hematopoietic stem cells. Novel evidence of the occurrence of NAD(P)H oxidase activity. J Biol Chem 2005; 280: 26467-26476.
58. Sardina JL, Lopez-Ruano G, Sanchez-Abarca LI, Perez-Simon JA, Gaztelumendi A, Trigueros C et al. p22phox-dependent NADPH oxidase activity is required for megakaryocytic differentiation. Cell Death Differ 2010; 17: 1842-1854.
59. Mostafa SS, Miller WM, Papoutsakis ET. Oxygen tension influences the differentiation, maturation and apoptosis of human megakaryocytes. Br J Haematol 2000; 111: 879-889.
60. McCrann DJ, Eliades A, Makitalo M, Matsuno K, Ravid K. Differential expression of NADPH oxidases in megakaryocytes and their role in polyploidy. Blood 2009; 114: 1243-1249.
61. Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R et al. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 1999; 93: 2928-2935.
62. Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009; 23: 1432-1440.
63. Mazharian A, Watson SP, Severin S. Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation. Exp Hematol 2009; 37: 1238-1249.
64. Ruiz-Gines JA, Lopez-Ongil S, Gonzalez-Rubio M, Gonzalez-Santiago L, Rodriguez-Puyol M, Rodriguez-Puyol D. Reactive oxygen species induce proliferation of bovine aortic endothelial cells. J Cardiovasc Pharmacol 2000; 35: 109-113.
65. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181-189.
66. del Bello B, Paolicchi A, Comporti M, Pompella A, Maellaro E. Hydrogen peroxide produced during gamma-glutamyl transpeptidase activity is involved in prevention of apoptosis and maintainance of proliferation in U937 cells. FASEB J 1999; 13: 69-79.
67. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med 1998; 132: 9-15.
68. Wartenberg M, Diedershagen H, Hescheler J, Sauer H. Growth stimulation versus induction of cell quiescence by hydrogen peroxide in prostate tumor spheroids is encoded by the duration of the Ca(2\+) response. J Biol Chem 1999; 274: 27759-27767.
69. Havens CG, Ho A, Yoshioka N, Dowdy SF. Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol Cell Biol 2006; 26: 4701-4711.
70. Pallotta I, Lovett M, Rice W, Kaplan DL, Balduini A. Bone marrow osteoblastic niche: a new model to study physiological regulation of megakaryopoiesis. PLoS One 2009; 4: e8359.
71. Kaushansky K. The enigmatic megakaryocyte gradually reveals its secrets. Bioessays 1999; 21: 353-360.
72. Szalai G, LaRue AC, Watson DK. Molecular mechanisms of megakaryopoiesis. Cell Mol Life Sci 2006; 63: 2460-2476.
73. Xanthoudakis S, Miao G, Wang F, Pan YC, Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J 1992; 11: 3323-3335.
74. Prata C, Maraldi T, Zambonin L, Fiorentini D, Hakim G, Landi L. ROS production and Glut1 activity in two human megakaryocytic cell lines. Biofactors 2004; 20: 223-233.
75. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185.
76. Yoshida K, Kirito K, Yongzhen H, Ozawa K, Kaushansky K, Komatsu N. Thrombopoietin (TPO) regulates HIF-1alpha levels through generation of mitochondrial reactive oxygen species. Int J Hematol 2008; 88: 43-51.
77. LaIuppa JA, Papoutsakis ET, Miller WM. Oxygen tension alters the effects of cytokines on the megakaryocyte, erythrocyte, and granulocyte lineages. Exp Hematol 1998; 26: 835-843.
78. McCrann DJ, Yang D, Chen H, Carroll S, Ravid K. Upregulation of Nox4 in the aging vasculature and its association with smooth muscle cell polyploidy. Cell Cycle 2009; 8: 902-908.
79. Eliades A, Papadantonakis N, Ravid K. New roles for cyclin E in megakaryocytic polyploidization. J Biol Chem 2010; 285: 18909-18917.
80. Wang Z, Zhang Y, Lu J, Sun S, Ravid K. Mpl ligand enhances the transcription of the cyclin D3 gene: a potential role for Sp1 transcription factor. Blood 1999; 93: 4208-4221.
81. Wang Z, Sicinski P, Weinberg RA, Zhang Y, Ravid K. Characterization of the mouse cyclin D3 gene: exon/intron organization and promoter activity. Genomics 1996; 35: 156-163.
82. Garcia P, Frampton J, Ballester A, Cales C. Ectopic expression of cyclin E allows nonendomitotic megakaryoblastic K562 cells to establish re-replication cycles. Oncogene 2000; 19: 1820-1833.
83. Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007; 317: 1767-1770.
84. O'Brien JJ, Spinelli SL, Tober J, Blumberg N, Francis CW, Taubman MB et al. 15-Deoxy-D12,14-PGJ2 enhances platelet production from megakaryocytes. Blood 2008; 112: 4051-4060.
85. Mostafa SS, Papoutsakis ET, Miller WM. Oxygen tension modulates the expression of cytokine receptors, transcription factors, and lineage-specific markers in cultured human megakaryocytes. Exp Hematol 2001; 29: 873-883.
86. Mehaffey MG, Newton AL, Gandhi MJ, Crossley M, Drachman JG. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood 2001; 98: 2681-2688.
87. Lecine P, Villeval JL, Vyas P, Swencki B, Xu Y, Shivdasani RA. Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes. Blood 1998; 92: 1608-1616.
88. Battinelli E, Loscalzo J. Nitric oxide induces apoptosis in megakaryocytic cell lines. Blood 2000; 95: 3451-3459.
89. Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J. Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc Natl Acad Sci USA 2001; 98: 14458-14463.
90. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100: 350-356.
91. Zhang P, Wang YZ, Kagan E, Bonner JC. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J Biol Chem 2000; 275: 22479-22486.
92. Motohashi H, Katsuoka F, Engel JD, Yamamoto M. Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc Natl Acad Sci USA 2004; 101: 6379-6384.
93. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322.
94. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD, Yamamoto M. Genetic evidence that small maf proteins are essential for the activation of antioxidant response elementdependent genes. Mol Cell Biol 2005; 25: 8044-8051.
95. Chen Z, Hu M, Shivdasani RA. Expression analysis of primary mouse megakaryocyte differentiation and its application in identifying stage-specific molecular markers and a novel transcriptional target of NF-E2. Blood 2007; 109: 1451-1459.
96. Igarashi K, Kataoka K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M. Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. Nature 1994; 367: 568-572.
97. Motohashi H, Katsuoka F, Shavit JA, Engel JD, Yamamoto M. Positive or negative MARE-dependent transcriptional regulation is determined by the abundance of small Maf proteins. Cell 2000; 103: 865-875.
98. Motohashi H, Kimura M, Fujita R, Inoue A, Pan X, Takayama M et al. NF-E2 domination over Nrf2 promotes ROS accumulation and megakaryocytic maturation. Blood 2010; 115: 677-686.
99. Blair P, Rex S, Vitseva O, Beaulieu L, Tanriverdi K, Chakrabarti S et al. Stimulation of Tolllike receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res 2009; 104: 346-354.
100. Beaulieu LM, Lin E, Morin KM, Tanriverdi K, Freedman JE. Regulatory effects of TLR2 on megakaryocytic cell function. Blood 2011; 117: 5963-5974.
101. Ray DM, Akbiyik F, Phipps RP. The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. J Immunol 2006; 177: 5068-5076.
102. Siddiqui NF, Shabrani NC, Kale VP, Limaye LS. Enhanced generation of megakaryocytes from umbilical cord blood-derived CD34(\+) cells expanded in the presence of two nutraceuticals, docosahexanoic acid and arachidonic acid, as supplements to the cytokine-containing medium. Cytotherapy 2011; 13: 114-128.
103. Wang WQ, Zhang HF, Gao GX, Bai QX, Li R, Wang XM. Adiponectin inhibits hyperlipidemia-induced platelet aggregation via attenuating oxidative/nitrative stress. Physiol Res 2011; 60: 347-354.
104. Iuliano L, Pratico D, Ghiselli A, Bonavita MS, Violi F. Superoxide dismutase triggers activation of 'primed' platelets. Arch Biochem Biophys 1991; 289: 180-183.
105. Handin RI, Karabin R, Boxer GJ. Enhancement of platelet function by superoxide anion. J Clin Invest 1977; 59: 959-965.
106. Ambrosio G, Golino P, Pascucci I, Rosolowsky M, Campbell WB, DeClerck F et al. Modulation of platelet function by reactive oxygen metabolites. Am J Physiol 1994; 267: H308-H318.
107. Del Principe D, Menichelli A, De Matteis W, Di Corpo ML, Di Giulio S, Finazzi-Agro A. Hydrogen peroxide has a role in the aggregation of human platelets. FEBS Lett 1985; 185: 142-146.
108. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F, Pignatelli BP. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998; 91: 484-490.
109. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001; 103: 399-409.
110. Savini I, Arnone R, Rossi A, Catani MV, Del Principe D, Avigliano L. Redox modulation of Ecto-NOX1 in human platelets. Mol Membr Biol 2010; 27: 160-169.
111. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109: 1819-1822.
112. Clutton P, Miermont A, Freedman JE. Regulation of endogenous reactive oxygen species in platelets can reverse aggregation. Arterioscler Thromb Vasc Biol 2004; 24: 187-192.
113. Ferroni P, Vazzana N, Riondino S, Cuccurullo C, Guadagni F, Davi G. Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal 2012; 17: 1447-1485.
114. Schildknecht S, van der Loo B, Weber K, Tiefenthaler K, Daiber A, Bachschmid MM. Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets. Free Radic Biol Med 2008; 45: 512-520.
115. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM et al. NAD(P)H oxidasedependent platelet superoxide anion release increases platelet recruitment. Blood 2002; 100: 917-924.
116. Begonja AJ. NO/cGMP and ROS pathways in regulation of platelet function and megakaryocyte maturation. Disertation, Julius-Maximilians University: Wurzburg, 2007.
117. Krotz F, Sohn HY, Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 2004; 24: 1988-1996.
118. O'Brien JJ, Baglole CJ, Garcia-Bates TM, Blumberg N, Francis CW, Phipps RP. 15-Deoxy-Delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis. J Thromb Haemost 2009; 7: 182-189.
119. Wang J, Li L, Cang H, Shi G, Yi J. NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res 2008; 32: 429-436.
120. Lu J, Chew EH, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 2007; 104: 12288-12293.
121. Peeters K, Stassen JM, Collen D, Van Geet C, Freson K. Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov Today 2008; 13: 798-806.
122. Rivera J, Lozano ML, Navarro-Nunez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009; 94: 700-711.
123. Pleines I, Hagedorn I, Gupta S, May F, Chakarova L, van Hengel J et al. Megakaryocytespecific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood 2012; 119: 1054-1063.
124. Antoniades C, Bakogiannis C, Tousoulis D, Demosthenous M, Marinou K, Stefanadis C. Platelet activation in atherogenesis associated with low-grade inflammation. Inflamm Allergy Drug Targets 2010; 9: 334-345.
125. Monteiro PF, Morganti RP, Delbin MA, Calixto MC, Lopes-Pires ME, Marcondes S et al. Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production. Cardiovasc Diabetol 2012; 11: 1-9.
126. Lakshmi SV, Padmaja G, Kuppusamy P, Kutala VK. Oxidative stress in cardiovascular disease. Indian J Biochem Biophys 2009; 46: 421-440.
127. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18: 655-673.
128. Zhang N, Andresen BT, Zhang C. Inflammation and reactive oxygen species in cardiovascular disease. World J Cardiol 2010; 2: 408-410.
129. Bae JS. Antithrombotic and profibrinolytic activities of phloroglucinol. Food Chem Toxicol 2011; 49: 1572-1577.
130. Li Y, Qian ZJ, Ryu B, Lee SH, Kim MM, Kim SK. Chemical components and its antioxidant properties in vitro: an edible marine brown alga, Ecklonia cava. Bioorg Med Chem 2009; 17: 1963-1973.
131. Chang MC, Chang HH, Chan CP, Chou HY, Chang BE, Yeung SY et al. Antiplatelet effect of phloroglucinol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Toxicol Appl Pharmacol 2012; 263: 287-295.
132. Fassett RG, Coombes JS. Astaxanthin: a potential therapeutic agent in cardiovascular disease. Mar Drugs 2011; 9: 447-465.
133. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res 2005; 68: 26-36.
134. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 1994; 11: 95-102.
135. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471-478.
136. Diatchuk V, Lotan O, Koshkin V, Wikstroem P, Pick E. Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J Biol Chem 1997; 272: 13292-13301.
137. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011; 10: 453-471.